Multicenter, Randomized, Double-blind, Two-period, Placebo Controlled, Forced-titration Proof of Concept Crossover Study to Compare QGC001 With Placebo in Patients With Grade I or II Essential Hypertension.
Phase of Trial: Phase II
Latest Information Update: 14 Sep 2017
At a glance
- Drugs Firibastat (Primary)
- Indications Essential hypertension
- Focus Proof of concept; Therapeutic Use
- Acronyms 2QG1
- Sponsors Quantum Genomics
- 10 Jun 2017 Biomarkers information updated
- 26 Apr 2016 Status changed from recruiting to completed, according to a Quantum Genomics media release.
- 13 Jul 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History